Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10987845 | 1.00 | MAPT (0.69) | MAPTRXFP1MAOBHDAC3MAPK1 | |
| SCHEMBL224789 | 0.98 | MAPT (0.66) | MAPTRXFP1MAOBHDAC3MAPK1 | |
| SCHEMBL434792 | 0.92 | SMN1; SMN2 (0.67) | MAPTRXFP1MAOBHDAC3MAPK1 | |
| SCHEMBL9671779 | 0.90 | MAPT (0.83) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL3814880 | 0.90 | MAPT (0.83) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL7827144 | 0.88 | MAPT (0.80) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL7065645 | 0.88 | MAPT (0.79) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL11760587 | 0.87 | SMN1; SMN2 (0.60) | MAPTRXFP1MAOBHDAC3MAPK1 | |
| SCHEMBL9329305 | 0.86 | MAPT (0.66) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL31577196 | 0.86 | MAOB (0.55) | MAPTRXFP1MAOBHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691845-A4 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-02-25 | — | — | EP | disclosed |
| CN-1874792-A | Compounds containing matrix metalloproteinase substrates and methods of their use | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-12-06 | — | — | CN | disclosed |
| EP-1691845-A1 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | Bristol-Myers Squibb Pharma Company (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | LANTHEUS MEDICAL IMAGING, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023314-A1 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | MMP1, MMP10, MMP8 | MAPT 2533/4885RXFP1 2548/4885MAOB 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.